The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis
Abstract
PURPOSE: To evaluate the efficacy and safety of a slow-release formulation of cytarabine (DepoCyt; Chiron Corp, Emeryville, CA, and Skye Pharma, Inc, San Diego, CA) that maintains cytotoxic concentrations of cytarabine (ara-C) in the CSF of most patients for more than 14 days. PATIENTS AND METHODS: Twenty-eight patients with lymphoma and a positive CSF cytology were randomized to receive DepoCyt 50 mg once every 2 weeks or free ara-C 50 mg twice a week for 1 month. Patients whose CSF cytology converted to negative and who did not have neurologic progression received an additional 3 months of consolidation therapy and then 4 months of maintenance therapy. All patients received dexamethasone 4 mg orally bid on days 1 through 5 of each 2-week cycle. RESULTS: The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P = .006). All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen. Time to neurologic progression and survival trended in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P > .05). DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P = .041). The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease. CONCLUSION: DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graham, F. L., & Whitmore, G. F. (1970) · PubMed · Cited by 208
Leptomeningeal metastases from solid tumors
Bokstein, F., Lossos, A., & Siegal, T. (1998) · Cancer · Cited by 155
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
Kim, S., Chatelut, É., Kim, J. C., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2186 · Cited by 153
Bokstein, F., Lossos, A., & Siegal, T. (1998) · PubMed · Cited by 153
Cytosine arabinoside cerebrospinal fluid kinetics
Zimm, S., Collins, J. M., Miser, J. S., Chatterji, D. C., & Poplack, D. G. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.120 · Cited by 140
Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis
Litam, J., Cabanillas, F., Smith, T., et al. (1979) · Blood · doi:10.1182/blood.v54.6.1249.1249 · Cited by 115
Kohn, F. R., Malkmus, S. A., Brownson, E. A., Rossi, S. S., & Yaksh, T. L. (1998) · Drug Delivery · doi:10.3109/10717549809031390 · Cited by 31
Cited by
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Nanoparticles in cellular drug delivery
Faraji, A. H., & Wipf, P. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.043 · Cited by 903
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Metadata
- Authors
- Glantz, M. J., LaFollette, S., Jaeckle, K. A., Shapiro, W., Swinnen, L., Rozental, J. R., Phuphanich, S., Rogers, L. R., Gutheil, J. C., Batchelor, T., Lyter, D., Chamberlain, M., Maria, B. L., Schiffer, C., Bashir, R., Thomas, D., Cowens, W., & Howell, S. B.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-10
- Volume
- 17
- Issue
- 10
- Pages
- 3110-3116
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1907780553
- Cited by
- 402
- References
- 7
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. https://app.cochat.ai/papers/10.1200/jco.1999.17.10.3110
- The paper
- Glantz, M. J., LaFollette, S., Jaeckle, K. A., Shapiro, W., Swinnen, L., Rozental, J. R., Phuphanich, S., Rogers, L. R., Gutheil, J. C., Batchelor, T., Lyter, D., Chamberlain, M., Maria, B. L., Schiffer, C., Bashir, R., Thomas, D., Cowens, W., & Howell, S. B. (1999). Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.10.3110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.